Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).

Chen R. W., Ansell S. M., Gallamini A., Connors J. M., Savage K. J., Collins G. P., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded, Scopus)

• Publication Type: Article / Abstract
• Volume: 36 Issue: 15
• Publication Date: 2018
• Doi Number: 10.1200/jco.2018.36.15_suppl.7539
• Journal Name: JOURNAL OF CLINICAL ONCOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Hacettepe University Affiliated: Yes